Drug recall · May 10, 2023
Glimepiride USP recall
Why: CGMP deviations.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Glimepiride USP, 4 mg, 90 count-bottles, Rx only, Intas Pharm. Limited Pkg By: PD-Rx Pharmaceuticals Incorporated Oklahoma City, OK 73127, NDC 43063-0587-90
- Lots / codes
Lots: A22B45 Exp. 01/31/24; C22A73, E22E41, C22D28, F22B68, G22A29, H22B97, K22A36 Exp. 03/31/24; K22B99, A23D07, B23B25 Exp. 10/31/24; B23B55 Exp. 06/30/25
- Quantity
- 186 bottles
- Company
- PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK
- Distribution
- Nationwide in the US.
- Initiated
- April 6, 2023 · Voluntary: Firm initiated
- Classified
- May 1, 2023
- Reported
- May 10, 2023
- Ended
- April 30, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Glimepiride
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.